STOCK TITAN

Medtronic plc - MDT STOCK NEWS

Welcome to our dedicated page for Medtronic plc news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic plc stock.

Medtronic plc (NYSE: MDT) is an American medical device company with its operational and executive headquarters in Minneapolis, Minnesota, and legal headquarters in Dublin, Ireland, following its acquisition of Covidien in 2015. As one of the largest medical-device companies globally, Medtronic specializes in developing and manufacturing therapeutic medical devices for chronic diseases.

The company’s extensive product portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. It markets these products to healthcare institutions and physicians worldwide, with international sales accounting for approximately 50% of its total revenue.

In a recent announcement on April 10, 2024, Medtronic unveiled significant advancements in artificial intelligence (AI) for endoscopic care through the launch of ColonPRO™ software for the GI Genius™ intelligent endoscopy system. This new software improves polyp detection and introduces procedural highlights to enhance physicians' workflow. The company has also entered into a collaboration with Modernizing Medicine® to integrate AI-driven data with electronic health records (EHR).

Medtronic recently reported its financial results for the fourth quarter and fiscal year 2024, showcasing a global revenue of $32.364 billion, a 3.6% increase compared to the previous year. The company's revenue growth was fueled by advancements in its Cardiovascular, Neuroscience, Medical Surgical, and Diabetes portfolios.

In addition to its financial performance, Medtronic has made strides in technological innovation. The U.S. FDA approved the Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS) for chronic pain treatment, demonstrating the company’s commitment to addressing unmet clinical needs and improving patient care through advanced technologies.

Medtronic remains dedicated to its mission of alleviating pain, restoring health, and extending life, driven by a global team of over 95,000 employees across 150 countries. The company continues to leverage its diverse knowledge and insatiable curiosity to deliver innovative solutions that transform lives. For more information, visit Medtronic's official website.

Rhea-AI Summary

Virtua Health and Medtronic plc (NYSE:MDT) have announced a five-year partnership aimed at enhancing care delivery in South Jersey, particularly for underserved populations. This collaboration will leverage technology to address health disparities, focusing on heart health and outpatient continuity. Medtronic LABS will support initiatives like food access programs, working alongside the Cherry Hill Free Clinic to improve chronic condition management. Key projects include optimizing heart failure care and expanding home hospitalization services, which are set to officially launch in early 2022. The partnership aims to foster health equity and improve patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.04%
Tags
none
-
Rhea-AI Summary

Medtronic plc (NYSE:MDT) received a warning letter from the FDA on December 9, 2021, concerning its Northridge, California facility, primarily addressing quality system inadequacies linked to the MiniMed™ insulin infusion pumps. The letter followed an inspection completed in July 2021 and highlighted issues in risk assessment, complaint handling, and device recalls. Medtronic is focused on resolving these issues with internal and external resources, emphasizing its commitment to product safety and the well-being of diabetes patients. No actions are recommended for patients or healthcare providers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.04%
Tags
none
-
Rhea-AI Summary

Medtronic has received FDA 510(k) clearance for its INVOS™ 7100 system, facilitating enhanced monitoring of organ-specific oxygen levels in pediatric patients from birth to 18 years. This system is designed to alert clinicians to critical changes in patient conditions, aiding in timely interventions for vulnerable neonates and children. With real-time measurements of tissue perfusion and oxygenation, the INVOS™ 7100 is expected to improve clinical outcomes. The technology will be commercially available in spring 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
none
Rhea-AI Summary

Medtronic plc (NYSE: MDT) announced a study in Osteoporosis International showing significant reductions in oral opioid use and payer costs after balloon kyphoplasty (BKP) or vertebroplasty (VP) for vertebral compression fractures (VCF). Of patients studied, 57.1% decreased opioid use, with an average payer cost savings of $6,759 over six months. The findings suggest potential benefits in managing pain and reducing opioid reliance in patients. This is the first study prioritizing opioid reduction as a primary outcome.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
-
Rhea-AI Summary

Medtronic plc (NYSE:MDT) announced a $0.63 cash dividend for Q3 of fiscal 2022, marking a 9% increase from the previous year. This increase reinforces its position as a member of the S&P 500 Dividend Aristocrats, with 44 consecutive years of dividend growth. The dividend will be payable on January 14, 2022, to shareholders of record by December 22, 2021. Medtronic is recognized for its innovative healthcare solutions and has a workforce of over 90,000 globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
dividends earnings
-
Rhea-AI Summary

Medtronic (NYSE:MDT) reported a second-quarter revenue of $7.847 billion, up 3% year-over-year, with organic growth of 2%. GAAP diluted EPS was $0.97, a 169% increase. Second-quarter U.S. revenue of $3.997 billion declined 1%, while emerging markets surged 20%. The company revised fiscal year 2022 organic revenue growth expectations to 7-8% from 9%. Despite challenges from COVID-19 and labor shortages affecting procedures, Medtronic remains optimistic about growth due to a strong pipeline and operational improvements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
Rhea-AI Summary

Medtronic (NYSE:MDT) has received FDA 510(k) clearance for its PillCam™ Small Bowel 3 system, enabling remote endoscopy procedures through the PillCam SB3 @HOME program. This innovation allows patients to undergo telehealth procedures for detecting gastrointestinal issues such as Crohn's disease and obscure bleeding from home. The system captures approximately 50,000 images during the procedure, which are securely transmitted for diagnostic review, enhancing patient safety and convenience. This marks a significant development in remote healthcare technology, especially post-pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
none
-
Rhea-AI Summary

Medtronic plc (NYSE:MDT) announced four key executive appointments to enhance its healthcare technology leadership. Bob Hopkins becomes head of global strategy, Mei Jiang takes on the role of global digital innovation leader, while Harry 'Skip' Kiil and Mira Sahney will lead the Cranial and Spinal Technologies and Pelvic Health Operating Units, respectively. These appointments aim to bring diverse expertise and accelerate innovation in a rapidly evolving medical technology landscape, furthering Medtronic's mission to deliver transformative healthcare solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
none
Rhea-AI Summary

Medtronic plc (NYSE:MDT) will announce its financial results for Q2 FY2022 on November 23, 2021, at approximately 5:45 a.m. CST. The results will cover the quarter ending October 29, 2021. A video webcast to discuss these results will take place at 7:00 a.m. CST on the same day. Medtronic is scheduled to report its Q3 and Q4 results in February and May 2022, respectively. The company, based in Dublin, focuses on healthcare technology solutions, aiming to alleviate pain and restore health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags

FAQ

What is the current stock price of Medtronic plc (MDT)?

The current stock price of Medtronic plc (MDT) is $86.21 as of November 22, 2024.

What is the market cap of Medtronic plc (MDT)?

The market cap of Medtronic plc (MDT) is approximately 109.1B.

What does Medtronic plc specialize in?

Medtronic specializes in developing and manufacturing therapeutic medical devices for chronic diseases, including pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools.

Where are Medtronic’s headquarters located?

Medtronic’s operational and executive headquarters are in Minneapolis, Minnesota, while its legal headquarters are in Dublin, Ireland, following its acquisition of Covidien in 2015.

How significant are Medtronic’s international sales?

International sales account for roughly 50% of Medtronic’s total revenue.

What recent advancements has Medtronic made in AI for healthcare?

Medtronic recently launched the ColonPRO™ software for the GI Genius™ intelligent endoscopy system, enhancing AI-driven polyp detection and procedural highlights. The company also partnered with Modernizing Medicine® to integrate AI data with EHR systems.

What are Medtronic’s recent financial achievements?

Medtronic reported a global revenue of $32.364 billion for fiscal year 2024, a 3.6% increase from the previous year, driven by growth in its Cardiovascular, Neuroscience, Medical Surgical, and Diabetes portfolios.

What new technology has Medtronic introduced for chronic pain treatment?

Medtronic introduced the Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS), which the U.S. FDA approved for the treatment of chronic pain.

How many employees does Medtronic have worldwide?

Medtronic has a global team of over 95,000 employees across 150 countries.

What is Medtronic’s mission?

Medtronic's mission is to alleviate pain, restore health, and extend life.

Where can I find more information about Medtronic?

For more information about Medtronic, visit their official website at Medtronic.com.

How does Medtronic approach innovation in healthcare?

Medtronic leverages its diverse knowledge, insatiable curiosity, and commitment to helping those in need to deliver innovative technologies that transform lives, focusing on engineering extraordinary healthcare solutions.

Medtronic plc

NYSE:MDT

MDT Rankings

MDT Stock Data

109.06B
1.28B
0.26%
85.42%
0.79%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
GALWAY